| ZD1839治疗恶性纤维组织细胞瘤术后两肺转移1例报告 |
| |
| 引用本文： | 张康,罗荣城,谢剑明,钟运超,郭胜春,张振胜.ZD1839治疗恶性纤维组织细胞瘤术后两肺转移1例报告[J].解放军医学杂志,2004,29(2):170-171. |
| |
| 作者姓名： | 张康 罗荣城 谢剑明 钟运超 郭胜春 张振胜 |
| |
| 作者单位： | 543000,梧州,广西梧州市人民医院;第一军医大学南方医院 |
| |
| 摘 要： | 恶性纤维组织细胞瘤是一种常见的软组织肿瘤，恶性程度高，易发生转移，预后差，术后放疗和化疗的作用有限。本文报道了1例恶性纤维组织细胞瘤术后两肺转移患者，肿瘤细胞表皮生长因子受体（EGFR）表达阳性，采用EGFR酷氨酸激本科抑制剂ZD1839治疗1个疗程（28天）后，两肺转移灶全部消失，达到完全缓解。
|
| 关 键 词： | 恶性纤维组织细胞瘤 ZD1839 分子靶向治疗 |
| 修稿时间： | 2003年11月19 |
Successful treatment of pulmonary metastases of malignant fibrous histiocytoma with ZD1839:a case report |
| |
| Abstract: | Malignant fibrous histiocytoma (MFH) is a common soft tissue sarcoma, which shows a strong predilection for distant metastases. Due to its limited response to radiotherapy and chemotherapy , poor prognosis is generally observed. A patient with MFH, who developed pulmonary metastases, postoperatively took ZD1839, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, because it was found that there was EGFR expression on the surface of the tumor cells. After a course of treatment (28 days), the pulmonary metastases disappeared, and the patient enjoyed a complete remission. |
| |
| Keywords: | malignant fibrous histiocytoma ZD1839 molecular target therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
